On July 1, 2018, the U.S. Pharmacopeial Convention (USP) General Chapter <800> will go into effect, including the required use of a closed-system drug-transfer device (CSTD) for cytotoxic agents. In the following Q&A interview, James Jorgenson, MS, RPh, FASHP, the CEO of Visante Inc., makes the case for why a CSTD is so vital to the safe preparation and administration of hazardous drugs, and why pharmacy and nursing need to approach the selection of an appropriate system with the same